News Releases

Date	Title and Summary	View
Jun 26, 2020	Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Jun 15, 2020	New Phase 3 Data for TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Show Consistent, High Levels of Skin Clearance Through Four Years in Adult Patients with Moderate to Severe Plaque Psoriasis
Jun 13, 2020	Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
Jun 10, 2020	Johnson & Johnson to Participate in Bank of America Virtual Conference
Jun 10, 2020	Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
Jun 04, 2020	Johnson & Johnson to Host Annual Health for Humanity Investor Webcast Health for Humanity Webcast to Highlight Company's Commitment to Lead and Meet Urgent Health Challenges Worldwide Live Investor Webcast Scheduled for June 18, 2020 at 8:00 a.m. ET NEW BRUNSWICK, N.J. , June 4, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), the world's largest and most
Jun 04, 2020	European Commission Grants Marketing Authorisation for DARZALEX®▼(daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications
May 27, 2020	U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO Ò (bedaquiline). SIRTURO ® is now indicated for use as part of combination
May 18, 2020	Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology and the Janssen Oncology Strategy and Portfolio NEW BRUNSWICK, N.J. , May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the virtual 2020 American Society of Clinical
May 18, 2020	Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations